-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Maze Therapeutics, Lowers Price Target to $51

Benzinga·11/11/2026 16:32:21
Listen to the news
JP Morgan analyst Anupam Rama maintains Maze Therapeutics (NASDAQ:MAZE) with a Overweight and lowers the price target from $53 to $51.